Therapeutic Drug Monitoring of Antibiotics in Critically Ill Children : An Observational Study in a Pediatric Intensive Care Unit
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: Septic critically ill children are at a high risk of inadequate antibiotic exposure, requiring them to undergo therapeutic drug monitoring (TDM). The aim of this study was to describe the use of TDM for antibiotics in critically ill children.
METHODS: The authors conducted a single-center observational study between June and December 2019, with all children treated with antibiotics in a pediatric intensive care unit located in a French university hospital. Standard clinical and laboratory data were recorded. Blood samples were collected for routine laboratory tests, and plasma antibiotic levels were assayed using validated analytical methods.
RESULTS: A total of 209 children received antibiotics. TDM was performed in 58 patients (27.8%) who had a greater mean organ dysfunction (according to the International Pediatric Sepsis Consensus Conference) (3 versus 1 in the non-TDM group; P < 0.05) and were treated with antibiotics for longer. A total of 208 samples were analyzed. The median [interquartile range] assay turnaround time was 3 (1-5) days, and 48 (46.2%) of the 104 initial antibiotic concentration values were below the pharmacokinetic/pharmacodynamic targets. A total of 34 (46%) of the 74 off-target TDM measurements available before the end of the antibiotic treatment prompted dose adjustment. This dose adjustment increased the proportion of on-target TDM measurements (70% versus 20% without adjustment). Subsequent measurements of the minimum inhibitory concentration showed that the use of the European Committee on Antimicrobial Susceptibility Testing's epidemiological cutoff values led to underestimation of pharmacokinetic/pharmacodynamic target attainment in 10 cases (20%).
CONCLUSIONS: TDM seems to be an effective means of optimizing antibiotic exposure in critically ill children. This requires timely plasma antibiotic assays and minimum inhibitory concentration measurements. It is important to define which patients should undergo TDM and how this monitoring should be managed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Therapeutic drug monitoring - 44(2022), 2 vom: 01. Apr., Seite 319-327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Cacqueray, Noémie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.03.2022 Date Revised 14.08.2023 published: Print ClinicalTrials.gov: NCT02539407 Citation Status MEDLINE |
|---|
| doi: |
10.1097/FTD.0000000000000918 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338232907 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338232907 | ||
| 003 | DE-627 | ||
| 005 | 20231226000219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/FTD.0000000000000918 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338232907 | ||
| 035 | |a (NLM)35292609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Cacqueray, Noémie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Drug Monitoring of Antibiotics in Critically Ill Children |b An Observational Study in a Pediatric Intensive Care Unit |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.2022 | ||
| 500 | |a Date Revised 14.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02539407 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Septic critically ill children are at a high risk of inadequate antibiotic exposure, requiring them to undergo therapeutic drug monitoring (TDM). The aim of this study was to describe the use of TDM for antibiotics in critically ill children | ||
| 520 | |a METHODS: The authors conducted a single-center observational study between June and December 2019, with all children treated with antibiotics in a pediatric intensive care unit located in a French university hospital. Standard clinical and laboratory data were recorded. Blood samples were collected for routine laboratory tests, and plasma antibiotic levels were assayed using validated analytical methods | ||
| 520 | |a RESULTS: A total of 209 children received antibiotics. TDM was performed in 58 patients (27.8%) who had a greater mean organ dysfunction (according to the International Pediatric Sepsis Consensus Conference) (3 versus 1 in the non-TDM group; P < 0.05) and were treated with antibiotics for longer. A total of 208 samples were analyzed. The median [interquartile range] assay turnaround time was 3 (1-5) days, and 48 (46.2%) of the 104 initial antibiotic concentration values were below the pharmacokinetic/pharmacodynamic targets. A total of 34 (46%) of the 74 off-target TDM measurements available before the end of the antibiotic treatment prompted dose adjustment. This dose adjustment increased the proportion of on-target TDM measurements (70% versus 20% without adjustment). Subsequent measurements of the minimum inhibitory concentration showed that the use of the European Committee on Antimicrobial Susceptibility Testing's epidemiological cutoff values led to underestimation of pharmacokinetic/pharmacodynamic target attainment in 10 cases (20%) | ||
| 520 | |a CONCLUSIONS: TDM seems to be an effective means of optimizing antibiotic exposure in critically ill children. This requires timely plasma antibiotic assays and minimum inhibitory concentration measurements. It is important to define which patients should undergo TDM and how this monitoring should be managed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Boujaafar, Sana |e verfasserin |4 aut | |
| 700 | 1 | |a Bille, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Moulin, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Gana, Inès |e verfasserin |4 aut | |
| 700 | 1 | |a Benaboud, Sihem |e verfasserin |4 aut | |
| 700 | 1 | |a Hirt, Déborah |e verfasserin |4 aut | |
| 700 | 1 | |a Béranger, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Toubiana, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Renolleau, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Tréluyer, Jean M |e verfasserin |4 aut | |
| 700 | 1 | |a Oualha, Mehdi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic drug monitoring |d 1993 |g 44(2022), 2 vom: 01. Apr., Seite 319-327 |w (DE-627)NLM000962295 |x 1536-3694 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2022 |g number:2 |g day:01 |g month:04 |g pages:319-327 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/FTD.0000000000000918 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2022 |e 2 |b 01 |c 04 |h 319-327 | ||